Objective We reviewed the clinical safety profile of lacidipine with the help of the rather
comprehensive data file of the manufacturer. Although a number of prospective, randomly …

Objective: The aim was to review the clinical safety profile of lacidipine with the help of the
rather comprehensive datafile of the manufacturer-a novel approach which may be of some …

Eleven centers in Tuscany, Italy, recruited 96 patients (aged 21-75 years) with mild-to-
moderate essential hypertension [diastolic blood pressure (DBP) 95-115 mm Hg; systolic …

Selection of the appropriate dose of a new drug for initiation of treatment and then for
maintenance is a complicated task. It requires the careful assessment and weighing of …

The clinical safety of the new dihydropyridine calcium antagonist lacidipine was assessed in
14 clinical trials, including 1,372 patients treated with lacidipine and 687 treated with an …

Calcium channel blockers are increasingly used in the treatment of hypertension. Newer
calcium channel blockers of the dihydropyridine group have longer elimination half-lives …

Synopsis Lacidipine is an orally administered calcium channel blocker of the
dihydropyridine class, which shows selectivity for vascular smooth muscle over cardiac …

Lacidipine is a calcium antagonist of the dihydropyridine group that is highly selective for
vascular tissues. It has been tested during the last few years for the treatment of arterial …

This multicenter study was designed to assess the clinical efficacy and safety of the new
once-daily calcium antagonist lacidipine in the treatment of mild-to-moderate essential …

Similarities and dissimilarities of 3 third generation calcium antagonist (amlodipine,
lacidipine and lercanidipine) are presented. Lacidipine is characterized by prolonged …